08:00 , Nov 3, 2014 |  BioCentury  |  Strategy

Translation in Asia

The low concentration of entrepreneurs and venture money in the Asia-Pacific region means Johnson & Johnson 's newest innovation center will initially go about making early stage deals and investments differently than its counterparts in...
07:00 , May 7, 2007 |  BioCentury  |  Product Development

Shock value

Former Eli Lilly employees at Cardiome Pharma Corp. were largely responsible for last week's in-licensing deal for GED-aPC , a next-generation version of the pharma company's Xigris drotrecogin alfa drug for severe sepsis. Now, Cardiome's...
08:00 , Mar 5, 2007 |  BC Week In Review  |  Company News

Regeneron management update

Regeneron Pharmaceuticals Inc. (REGN), Tarrytown, N.Y.   Business: Cancer, Ophthalmic, Inflammation   Hired: Robert Terifay as SVP of commercial, formerly president and COO of Arginox Pharmaceuticals Inc. ; and Alain Thibault as VP of clinical...
07:00 , Jul 17, 2006 |  BioCentury  |  Strategy

Saying NO to asthma

The mechanisms that VEGF uses to exert its effects on endothelial cells have been studied in depth. For example, VEGF has been shown to induce proliferation, sprouting and migration of endothelial cells. In contrast, very...
07:00 , May 22, 2006 |  BC Week In Review  |  Clinical News

Tilarginine acetate injection: Phase III ongoing

A DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III TRIUMPH trial in 658 patients without modification. The recommendation came after data for the first 165 patients was reviewed. The DSMB will meet again...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Company News

Arginox management update

Arginox Pharmaceuticals Inc. , Redwood City, Calif.   Business: Cardiovascular   Hired: Robert Terifay as president and COO, formerly SVP commercial at Synta Pharmaceuticals Corp.  ...
08:00 , Jan 9, 2006 |  BioCentury  |  Finance

Money & milestones

Money & milestones Company Recent financing Date Raised Status North American companies Acologix Series C 12/20/05 $25.3 Ph III Affymax Series D 7/18/05 $60.0 Ph II Alimera Series B 11/30/05 $31.8 Mkt (OTC product); Ph...
01:11 , Jan 7, 2006 |  BC Extra  |  Company News

Arginox names Terifay president

Cardiovascular company Arginox (Redwood City, Calif.) hired Robert Terifay as president and COO. Previously, Terifay was SVP commercial at Synta (Lexington, Mass.)....
01:31 , Jan 5, 2006 |  BC Extra  |  Financial News

Aisling closes $550 million fund

Aisling Capital closed its Aisling Capital II fund at $550 million. The firm, which was spun out of Perseus-Soros Management, said it will invest primarily in companies that are developing biopharmaceuticals and life science technologies....
07:00 , Jul 4, 2005 |  BC Week In Review  |  Clinical News

Tilarginine acetate injection: Phase III started

Arginox began the double-blind, placebo-controlled, international Phase III TRIUMPH trial to treat cardiogenic shock in about 650 patients. Arginox Pharmaceuticals Inc. , Menlo Park, Calif.   Product: Tilarginine acetate injection (TAI)   Business: Cardiovascular  ...